NBC News 12/22/25: FDA approves Wegovy weight loss pill from Novo Nordisk

An excerpt:

“The Food and Drug Administration on Monday approved a pill version of Wegovy…The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that has been brought to market for weight loss…

In November, Novo Nordisk reached a deal with the Trump administration to sell the lowest dose of the pill for $149 a month for people who pay out of pocket, in exchange for tariff relief…

Phase 3 clinical trial results published in the New England Journal of Medicine found that people who took the highest dose of the Wegovy pill lost 16.6% of their body weight, on average, after 64 weeks, compared with 2.2% weight loss in the placebo group…

The company expects that the Wegovy pill will be available widely in January.”

Related blog posts:

• The Rise of Oral Obesity Therapies: Semaglutide and Orforglipron
• Weight Loss Efficacy of Cagrilintide and Semaglutide
• FDA Approves Semaglutide for MASH
• Head-to-Head: Tirzepatide Outperforms Semaglutide
• Semaglutide in Adolescent Obesity